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However, age along with religion and education became
the main predictors for the emotional models: social rela-
tionships and psychological aspects. Overall, age was the
most important sociodemographic variable except in the
Pain/Physical Discomfort domain where gender was most
important. In this case, men had signiﬁcantly lower scores
than women. CONCLUSIONS: Sociodemographics are
more strongly related to scores in the psychosocial
domains of health related quality of life with age being
the greatest single factor. Older individuals may be more
likely to attribute health to aspects unrelated to physi-
cal well being such as their outlook on life and social 
relationships.
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OBJECTIVES: To assess whether ﬁngerstick Interna-
tional Normalized Ratio (INR) devices lead to the same
warfarin dosing decisions as a standard method, investi-
gators commonly rely on mathematical formulas to esti-
mate clinical decision-making. Our investigation assessed
the degree to which these formulas predict actual clinical
(i.e. ‘dosing’) agreement of INR pairs. METHODS: Two
hundred two patients provided 3 INR measurements for
analysis: two from different ﬁngerstick devices and one
via reference laboratory. Actual dosing decisions (up,
down, no change) based on these INRs were made by
blinded clinicians. Actual dosing agreement based upon
the ﬁngerstick devices and the laboratory was used as a
standard to assess agreement between published, but
unvalidated, formulas. Bayesian hierarchical modeling
was used to rank the algorithms in order of their ability
to predict actual clinical decisions. An enhanced method
used bootstrapped smoothing splines to investigate agree-
ment as a function of POCT INR value. RESULTS: A
total of 14 formulas have been used to estimate warfarin
dosing decisions in 11 published investigations. The for-
mulas misclassiﬁed dosing agreement for between 19%
and 38% of paired INR values (mean: 27%). Formulas
generally misclassiﬁed fewer pairs for the device with 
less bias (range: 16%–30%) than more bias (range
23%–44%). The method that offered the best proxy (pos-
terior probability of being the best method = 70%) still
misclassiﬁed 19% of INR pairs. The smoothing spline
analysis showed that the misclassiﬁcation of pairs by
these formulas varies inconsistently throughout the INR
scale. We developed an improved formula that is likely
too complex clinical use. CONCLUSIONS: The unvali-
dated formulas routinely used to predict warfarin dosing
decision agreement misclassify a signiﬁcant proportion 
of paired INR values. More accurate formulas are too
complex to be practical. Therefore, dosing decisions
should be measured directly as opposed to predicted with
a formula.
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OBJECTIVES: The use of telemonitoring is receiving
increased recognition by providers and payers as a means
of decreasing healthcare costs while improving or stabi-
lizing patient outcomes. We compared hospitalizations
and ER visits for telemonitored patients before and after
they began telemonitoring. METHODS: We analyzed
415 CHF patients who were assigned HomMed SentryTM
telemonitors, an FDA-approved 510(k) device, between
October 1, 2001, and September 30, 2002. Admission
and discharge dates from telemonitoring service were
compared with standardized home health nursing 
assessments using the CMS-mandated Outcome and
Assessment Information Set (OASIS). Health status of
telemonitored patients was compared with 6509 CHF
patients from the ASK for AgenciesTM research database,
representing 218 home health agencies in 44 states. Com-
parison patients had OASIS assessments during the same
study period. Within-patient differences in the rate of hos-
pitalizations and ER visits per 100 days were reported for
telemonitored patients before and after telemonitoring.
RESULTS: Telemonitored CHF patients were more likely
to have poorly controlled CHF symptoms (45%) than
non-monitored patients (34%, p = .001), although mon-
itored and non-monitored patients were comparable on
age (78.8 vs. 79.2 years, p > .10) and estimated severity
of comorbid conditions (4.6 vs. 5.3 on a 0–16 scale, 
p > .10). Once CHF patients began telemonitoring, the
average decrease in hospitalizations was 3.2 admissions
per 100 homecare days (t = -1.98, p = .05) and decrease
in ER visits was 3.3 admissions per 100 homecare days
(t = -1.94, p = .05). CONCLUSIONS: Telemonitors are
a valuable tool for improving the functional status and
outcomes of homebound CHF patients. That telemoni-
tored CHF patients are more likely than other home-
bound CHF patients to have poorly controlled symptoms
suggests that home health agencies are assigning tele-
monitors to their most severe patients.
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OBJECTIVES: Poor adherence to antihypertensive regi-
mens has frequently been cited as a factor for failing to
achieve blood pressure goals in patients with hyperten-
sion. The objective of our study was to determine factors
associated with adherence to antihypertensive regimens in
members enrolled in a commercial managed care organi-
zation (MCO). METHODS: All members evaluated 
had a diagnosis of hypertension and were continuously
enrolled during the one-year study period. Severity of
illness was stratiﬁed by co-existing medical complications
associated with hypertension. Members receiving one or
more antihypertensive medications were the population
evaluated in our retrospective analysis. Average medica-
tion possession ratio (MPR) on all antihypertensive med-
ications was used as the primary adherence indicator in
this study. Factors evaluated included member age,
gender, severity of illness, number of concurrent antihy-
pertensive medications, dosing schedule, and sum of total
days supply of medication. Variable were evaluated using
a forward step-wise regression analysis. RESULTS: There
were 3306 members identiﬁed with hypertension in 
the MCO. MPR was evaluated in 2116 members on an-
tihypertensive medications. The mean age was 52.2 years
and 47% were female. The most common classes of anti-
hypertensive medications utilized were Calcium Channel
Blockers, ACE Inhibitors, and Diuretics. The regression
model for average MPR was signiﬁcant (F = 127.72, 
p < 0.001). Factors signiﬁcantly correlated with average
MPR were total days supply (b = 0.73, p < 0.001), age
(b = 0.08, p < 0.001), number of current medications 
(b = -.057, p < 0.001) and dosing schedule (b = 0.08, 
p < 0.001). CONCLUSIONS: A number of factors were
found to be signiﬁcant predictors of adherence to antihy-
pertensive medications. Members that were older and
received the drugs for longer periods of time had better
adherence. Adherence to medication tended to decrease
as the number of concurrent medications increased and
as the number of doses of medication taken per day
increased. Disease severity and gender were not found to
be signiﬁcant predictors of adherence.
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OBJECTIVE: The objective of this study was to evaluate
the effects of various statin doses on the attainment of
target LDL-Cholesterol (LDL-C) levels in clinical prac-
tice. METHODS: Patients newly initiated on atorvas-
tatin, ﬂuvastatin, pravastatin, or simvastatin from 1/99 to
6/99 were retrospectively identiﬁed from a southeastern
U.S. health plan database. Exclusion criteria included
statin therapy in the prior 6 months, less than 90 days of
statin therapy, switching of statin, use of combination
dyslipidemia therapy, and less than 18 months of contin-
uous plan enrollment. For each statin dose, attainment 
of target LDL-C based on NCEP ATP II guidelines was 
analyzed using univariate (unadjusted) and multivariate
(adjusted) logistic regression. Covariates utilized in the
adjusted analysis were age, gender, presence of athero-
sclerotic vascular disease, and difference between baseline
and target LDL-C. RESULTS: A total of 1938 statin dose
episodes from 1645 eligible patients (mean age = 66.3 ±
10.4 years, 47% male) were evaluated. Mean absolute
(percent) LDL-C reductions across statin dose ranges
were: atorvastatin [67–81mg/dL (39–43%)], ﬂuvastatin
[34–42mg/dL (21–26%)], pravastatin [39–45mg/dL
(24–26%)], and simvastatin [52–67mg/dL (32–38%)]. In
the unadjusted results, atorvastatin 20mg, ﬂuvastatin 
20mg and 40mg, pravastatin 20mg and 40mg, and sim-
vastatin 10mg had signiﬁcantly lower odds of attaining
NCEP II LDL-C target when compared to atorvastatin 
10mg. In the adjusted results, ﬂuvastatin 20mg and 
40mg, pravastatin 20mg and 40mg, and simvastatin 
10mg and 20mg had signiﬁcantly lower odds of attain-
ing NCEP II LDL-C target as compared to atorvastatin
10mg. CONCLUSIONS: Patients prescribed atorvastatin
10mg had greater odds of attaining their target LDL-C
level than patients prescribed all other statin doses in the
adjusted analysis except for simvastatin 40mg and ator-
vastatin 20mg.
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OBJECTIVES: To examine the clinical effectiveness of
amlodipine as monotherapy or in combination with other
antihypertensives in systolic blood pressure (SBP) control
and JNC IV goal attainment within a multi-center ambu-
latory care setting. METHODS: Hypertensive adults were
identiﬁed over a 4-year period (1998–2001) from a large
commercially available electronic medical record (EMR)
database covering over 360,000 US primary care patients.
Study patients were required to have initiated therapy
with amlodipine and have at least one BP measurement
within 6 months prior to and 12 months following the
index date. Those with a documented diagnosis of CHF
or prior use of calcium channel blockers were excluded.
Mean change in SBP was compared using multivariable
regression, controlling for differences in age, gender,
comorbid conditions, baseline SBP, and days between
beginning and ending BP reading. Incremental rates of
JNC VI goal attainment are also presented. RESULTS:
One thousand one hundred seventy-ﬁve patients were
identiﬁed. Mean baseline SBP was 159.5mmHg (SD:
19.5). Adjusted SBP reductions in mmHg (%) were 16.0
